Brief: PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb's first collaboration product candidate

PeptiDream

15/06/2016 07:48

June 15 (Reuters) - PeptiDream Inc  4587.T : 
     
    * Says it has earned a milestone for the dosing of a first 
patient in a clinical trial by its alliance partner, 
Bristol-Myers Squibb Company (BMS)  BMY.N   
    * Says this is the first program to enter clinical testing 
out of the discovery collaboration between the two companies     
  
    * Says the molecule being advanced in clinical testing 
was discovered by Bristol-Myers Squibb starting from an active 
lead macrocyclic compound identified by Peptidream using its 
PDPS technology and provided to BMS for further optimization 
     
    Source text in Japanese: https://goo.gl/GDOvVr 
    Further company Coverage:  4587.T   BMY.N  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724; 
Reuters Messaging: qiujing.li.thomsonreuters.com@reuters.net))